Current List of Laboratories and Instrumented Initial Testing Facilities Which Meet Minimum Standards To Engage in Urine Drug Testing for Federal Agencies, 46309-46310 [2011-19478]
Download as PDF
<![CDATA[
Federal Register / Vol. 76, No. 148 / Tuesday, August 2, 2011 / Notices
facilitate a series of workshops through
technical and logistical support aimed
at the enhancement and development of
support mechanisms that will foster the
implementation of an effective data
driven prevention service delivery
system. The grantee will also facilitate
the development of prevention core
competencies which can be used to
gauge the professional skill
development levels needed to
effectively implement data driven
prevention programs, practices and
policies that are goal directed and
outcomes based. Finally, the grant
allows for the provision of instrumental
quality assurance on the block grant
guidance, the web-based application
system and other SAMHSA program
activities.
NASADAD is in the unique position
to facilitate these activities because:
• NASADAD is the sole and unique
organization with a direct official
relationship with the Single State
Agencies (SSAs) and has a history of
collaboration with the Federal and State
government and other organizations that
represent issues of importance.
• NASADAD is the sole organization
that has been utilizing a Web-based
process to facilitate SSA dialogue on
SSA management, clinical program and
research issues practices within the
SSAs.
• NASADAD’s constituency and staff
are a repository of knowledge on State
issues related to substance abuse
treatment indicators and are
accountable for performance in the
SAPT Block Grant. This knowledge is
critical to the grant project.
FOR FURTHER INFORMATION CONTACT:
Shelly Hara, Substance Abuse and
Mental Health Services Administration,
1 Choke Cherry Road, Room 8–1095,
Rockville, MD 20857; telephone: (240)
276–2321; E-mail:
shelly.hara@samhsa.hhs.gov.
Cathy Friedman,
SAMHSA Public Health Analyst.
[FR Doc. 2011–19496 Filed 8–1–11; 8:45 am]
BILLING CODE 4162–20–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
erowe on DSK5CLS3C1PROD with NOTICES
Substance Abuse and Mental Health
Services Administration
Current List of Laboratories and
Instrumented Initial Testing Facilities
Which Meet Minimum Standards To
Engage in Urine Drug Testing for
Federal Agencies
Substance Abuse and Mental
Health Services Administration, HHS.
AGENCY:
VerDate Mar<15>2010
15:03 Aug 01, 2011
Jkt 223001
ACTION:
Notice.
The Department of Health and
Human Services (HHS) notifies Federal
agencies of the Laboratories and
Instrumented Initial Testing Facilities
(IITF) currently certified to meet the
standards of the Mandatory Guidelines
for Federal Workplace Drug Testing
Programs (Mandatory Guidelines). The
Mandatory Guidelines were first
published in the Federal Register on
April 11, 1988 (53 FR 11970), and
subsequently revised in the Federal
Register on June 9, 1994 (59 FR 29908);
September 30, 1997 (62 FR 51118);
April 13, 2004 (69 FR 19644); November
25, 2008 (73 FR 71858); December 10,
2008 (73 FR 75122); and on April 30,
2010 (75 FR 22809).
A notice listing all currently certified
Laboratories and Instrumented Initial
Testing Facilities (IITF) is published in
the Federal Register during the first
week of each month. If any Laboratory/
IITF’s certification is suspended or
revoked, the Laboratory/IITF will be
omitted from subsequent lists until such
time as it is restored to full certification
under the Mandatory Guidelines.
If any Laboratory/IITF has withdrawn
from the HHS National Laboratory
Certification Program (NLCP) during the
past month, it will be listed at the end
and will be omitted from the monthly
listing thereafter.
This notice is also available on the
Internet at https://
www.workplace.samhsa.gov and https://
www.drugfreeworkplace.gov.
SUMMARY:
Mrs.
Giselle Hersh, Division of Workplace
Programs, SAMHSA/CSAP, Room 2–
1042, One Choke Cherry Road,
Rockville, Maryland 20857; 240–276–
2600 (voice), 240–276–2610 (fax).
FOR FURTHER INFORMATION CONTACT:
The
Mandatory Guidelines were initially
developed in accordance with Executive
Order 12564 and section 503 of Public
Law 100–71. The ‘‘Mandatory
Guidelines for Federal Workplace Drug
Testing Programs’’, as amended in the
revisions listed above, requires {or set}
strict standards that Laboratories and
Instrumented Initial Testing Facilities
(IITF) must meet in order to conduct
drug and specimen validity tests on
urine specimens for Federal agencies.
To become certified, an applicant
Laboratory/IITF must undergo three
rounds of performance testing plus an
on-site inspection. To maintain that
certification, a Laboratory/IITF must
participate in a quarterly performance
testing program plus undergo periodic,
on-site inspections.
SUPPLEMENTARY INFORMATION:
PO 00000
Frm 00043
Fmt 4703
Sfmt 4703
46309
Laboratories and Instrumented Initial
Testing Facilities (IITF) in the applicant
stage of certification are not to be
considered as meeting the minimum
requirements described in the HHS
Mandatory Guidelines. A Laboratory/
IITF must have its letter of certification
from HHS/SAMHSA (formerly: HHS/
NIDA) which attests that it has met
minimum standards.
In accordance with the Mandatory
Guidelines dated November 25, 2008
(73 FR 71858), the following
Laboratories and Instrumented Initial
Testing Facilities (IITF) meet the
minimum standards to conduct drug
and specimen validity tests on urine
specimens:
Instrumented Initial Testing Facilities
(IITF)
None.
Laboratories
ACL Laboratories ≤8901 W. Lincoln
Ave. West Allis, WI 53227, 414–328–
7840/800–877–7016 (Formerly:
Bayshore Clinical Laboratory)
ACM Medical Laboratory, Inc., 160
Elmgrove Park, Rochester, NY 14624,
585–429–2264
Advanced Toxicology Network, 3560
Air Center Cove, Suite 101, Memphis,
TN 38118, 901–794–5770/888–290–
1150
Aegis Analytical Laboratories , 345 Hill
Ave., Nashville, TN 37210, 615–255–
2400 (Formerly: Aegis Sciences
Corporation, Aegis Analytical
Laboratories, Inc.)
Alere Toxicology Services, 1111 Newton
St., Gretna, LA 70053, 504–361–8989/
800–433–3823 (Formerly: Kroll
Laboratory Specialists, Inc.,
Laboratory Specialists, Inc.)
Alere Toxicology Services, 450
Southlake Blvd., Richmond, VA
23236, 804–378–9130 (Formerly: Kroll
Laboratory Specialists, Inc., Scientific
Testing Laboratories, Inc.; Kroll
Scientific Testing Laboratories, Inc.)
Baptist Medical Center-Toxicology
Laboratory, 11401 I–30, Little Rock,
AR 72209–7056, 501–202–2783
(Formerly: Forensic Toxicology
Laboratory Baptist Medical Center)
Clinical Reference Lab, 8433 Quivira
Road, Lenexa, KS 66215–2802, 800–
445–6917
Doctors Laboratory, Inc., 2906 Julia
Drive, Valdosta, GA 31602, 229–671–
2281
DrugScan, Inc., P.O. Box 2969, 1119
Mearns Road, Warminster, PA 18974,
215–674–9310
ElSohly Laboratories, Inc., 5 Industrial
Park Drive, Oxford, MS 38655, 662–
236–2609
E:\FR\FM\02AUN1.SGM
02AUN1
erowe on DSK5CLS3C1PROD with NOTICES
46310
Federal Register / Vol. 76, No. 148 / Tuesday, August 2, 2011 / Notices
Gamma-Dynacare Medical
Laboratories,* A Division of the
Gamma-Dynacare Laboratory
Partnership, 245 Pall Mall Street,
London, ONT, Canada N6A 1P4, 519–
679–1630
Laboratory Corporation of America
Holdings, 7207 N. Gessner Road,
Houston, TX 77040, 713–856–8288/
800–800–2387
Laboratory Corporation of America
Holdings, 69 First Ave., Raritan, NJ
08869, 908–526–2400/800–437–4986
(Formerly: Roche Biomedical
Laboratories, Inc.)
Laboratory Corporation of America
Holdings, 1904 Alexander Drive,
Research Triangle Park, NC 27709,
919–572–6900/800–833–3984
(Formerly: LabCorp Occupational
Testing Services, Inc., CompuChem
Laboratories, Inc.; CompuChem
Laboratories, Inc., A Subsidiary of
Roche Biomedical Laboratory; Roche
CompuChem Laboratories, Inc., A
Member of the Roche Group)
Laboratory Corporation of America
Holdings, 1120 Main Street,
Southaven, MS 38671, 866–827–8042/
800–233–6339 (Formerly: LabCorp
Occupational Testing Services, Inc.;
MedExpress/National Laboratory
Center)
LabOne, Inc. d/b/a Quest Diagnostics,
10101 Renner Blvd., Lenexa, KS
66219, 913–888–3927/800–873–8845
(Formerly: Quest Diagnostics
Incorporated; LabOne, Inc.; Center for
Laboratory Services, a Division of
LabOne, Inc.)
Maxxam Analytics,* 6740 Campobello
Road, Mississauga, ON, Canada L5N
2L8, 905–817–5700, (Formerly:
Maxxam Analytics Inc. NOVAMANN
(Ontario), Inc.)
MedTox Laboratories, Inc., 402 W.
County Road D, St. Paul, MN 55112,
651–636–7466/800–832–3244
MetroLab-Legacy Laboratory Services,
1225 NE 2nd Ave., Portland, OR
97232, 503–413–5295/800–950–5295
Minneapolis Veterans Affairs Medical
Center, Forensic Toxicology
Laboratory, 1 Veterans Drive,
Minneapolis, MN 55417, 612–725–
2088
National Toxicology Laboratories, Inc.,
1100 California Ave., Bakersfield, CA
93304, 661–322–4250/800–350–3515
One Source Toxicology Laboratory, Inc.,
1213 Genoa-Red Bluff, Pasadena, TX
77504, 888–747–3774 (Formerly:
University of Texas Medical Branch,
Clinical Chemistry Division; UTMB
Pathology-Toxicology Laboratory)
Pacific Toxicology Laboratories, 9348
DeSoto Ave., Chatsworth, CA 91311,
800–328–6942 (Formerly: Centinela
VerDate Mar<15>2010
15:03 Aug 01, 2011
Jkt 223001
Hospital Airport Toxicology
Laboratory)
Pathology Associates Medical
Laboratories, 110 West Cliff Dr.,
Spokane, WA 99204, 509–755–8991/
800–541–7891x7
Phamatech, Inc., 10151 Barnes Canyon
Road, San Diego, CA 92121, 858–643–
5555
Quest Diagnostics Incorporated, 1777
Montreal Circle, Tucker, GA 30084,
800–729–6432 (Formerly: SmithKline
Beecham Clinical Laboratories;
SmithKline Bio-Science Laboratories)
Quest Diagnostics Incorporated, 400
Egypt Road, Norristown, PA 19403,
610–631–4600/877–642–2216
(Formerly: SmithKline Beecham
Clinical Laboratories; SmithKline BioScience Laboratories)
Quest Diagnostics Incorporated, 8401
Fallbrook Ave., West Hills, CA 91304,
800–877–2520 (Formerly: SmithKline
Beecham Clinical Laboratories)
S.E.D. Medical Laboratories, 5601 Office
Blvd., Albuquerque, NM 87109, 505–
727–6300/800–999–5227
South Bend Medical Foundation, Inc.,
530 N. Lafayette Blvd., South Bend,
IN 46601, 574–234–4176 x1276
Southwest Laboratories, 4625 E. Cotton
Center Boulevard, Suite 177, Phoenix,
AZ 85040, 602–438–8507/800–279–
0027
St. Anthony Hospital Toxicology
Laboratory, 1000 N. Lee St.,
Oklahoma City, OK 73101, 405–272–
7052
STERLING Reference Laboratories, 2617
East L Street, Tacoma, Washington
98421, 800–442–0438
Toxicology & Drug Monitoring
Laboratory, University of Missouri
Hospital & Clinics, 301 Business Loop
70 West, Suite 208, Columbia, MO
65203, 573–882–1273
Toxicology Testing Service, Inc., 5426
N.W. 79th Ave., Miami, FL 33166,
305–593–2260
U.S. Army Forensic Toxicology Drug
Testing Laboratory, 2490 Wilson St.,
Fort George G. Meade, MD 20755–
5235, 301–677–7085
*The Standards Council of Canada (SCC)
voted to end its Laboratory Accreditation
Program for Substance Abuse (LAPSA)
effective May 12, 1998. Laboratories certified
through that program were accredited to
conduct forensic urine drug testing as
required by U.S. Department of
Transportation (DOT) regulations. As of that
date, the certification of those accredited
Canadian laboratories will continue under
DOT authority. The responsibility for
conducting quarterly performance testing
plus periodic on-site inspections of those
LAPSA-accredited laboratories was
transferred to the U.S. HHS, with the HHS’
NLCP contractor continuing to have an active
role in the performance testing and
PO 00000
Frm 00044
Fmt 4703
Sfmt 4703
laboratory inspection processes. Other
Canadian laboratories wishing to be
considered for the NLCP may apply directly
to the NLCP contractor just as U.S.
laboratories do.
Upon finding a Canadian laboratory to be
qualified, HHS will recommend that DOT
certify the laboratory (Federal Register, July
16, 1996) as meeting the minimum standards
of the Mandatory Guidelines published in the
Federal Register on April 30, 2010 (75 FR
22809). After receiving DOT certification, the
laboratory will be included in the monthly
list of HHS-certified laboratories and
participate in the NLCP certification
maintenance program.
Dated: July 25, 2011.
Janine Denis Cook,
Chemist, Division of Workplace Programs,
CSAP/SAMHSA.
[FR Doc. 2011–19478 Filed 8–1–11; 8:45 am]
BILLING CODE 4160–20–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Substance Abuse and Mental Health
Services Administration
Notice of Meetings
Pursuant to Public Law 92–463,
notice is hereby given of the combined
meeting of the Substance Abuse and
Mental Health Services
Administration’s (SAMHSA) four
National Advisory Councils (the
SAMHSA National Advisory Council
(NAC), the Center for Mental Health
Services NAC, the Center for Substance
Abuse Prevention NAC, and the Center
for Substance Abuse Treatment NAC),
SAMHSA’s Advisory Committee for
Women’s Services, and SAMHSA’s
Tribal Technical Advisory Committee
on August 16, 2011.
The Councils were established to
advise the Secretary, Department of
Health and Human Services (HHS), the
Administrator, SAMHSA, and Center
Directors, concerning matters relating to
the activities carried out by and through
the Centers and the policies respecting
such activities.
Under Section 501 of the Public
Health Service Act, the Advisory
Committee for Women’s Services
(ACWS) is statutorily mandated to
advise the SAMHSA Administrator and
the Associate Administrator for
Women’s Services on appropriate
activities to be undertaken by SAMHSA
and its Centers with respect to women’s
substance abuse and mental health
services.
Pursuant to Presidential Executive
Order No. 13175, November 6, 2000,
and the Presidential Memorandum of
September 23, 2004, SAMHSA
established the Tribal Technical
E:\FR\FM\02AUN1.SGM
02AUN1
]]>Agencies
[Federal Register Volume 76, Number 148 (Tuesday, August 2, 2011)]
[Notices]
[Pages 46309-46310]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: 2011-19478]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Substance Abuse and Mental Health Services Administration
Current List of Laboratories and Instrumented Initial Testing
Facilities Which Meet Minimum Standards To Engage in Urine Drug Testing
for Federal Agencies
AGENCY: Substance Abuse and Mental Health Services Administration, HHS.
ACTION: Notice.
-----------------------------------------------------------------------
SUMMARY: The Department of Health and Human Services (HHS) notifies
Federal agencies of the Laboratories and Instrumented Initial Testing
Facilities (IITF) currently certified to meet the standards of the
Mandatory Guidelines for Federal Workplace Drug Testing Programs
(Mandatory Guidelines). The Mandatory Guidelines were first published
in the Federal Register on April 11, 1988 (53 FR 11970), and
subsequently revised in the Federal Register on June 9, 1994 (59 FR
29908); September 30, 1997 (62 FR 51118); April 13, 2004 (69 FR 19644);
November 25, 2008 (73 FR 71858); December 10, 2008 (73 FR 75122); and
on April 30, 2010 (75 FR 22809).
A notice listing all currently certified Laboratories and
Instrumented Initial Testing Facilities (IITF) is published in the
Federal Register during the first week of each month. If any
Laboratory/IITF's certification is suspended or revoked, the
Laboratory/IITF will be omitted from subsequent lists until such time
as it is restored to full certification under the Mandatory Guidelines.
If any Laboratory/IITF has withdrawn from the HHS National
Laboratory Certification Program (NLCP) during the past month, it will
be listed at the end and will be omitted from the monthly listing
thereafter.
This notice is also available on the Internet at https://www.workplace.samhsa.gov and https://www.drugfreeworkplace.gov.
FOR FURTHER INFORMATION CONTACT: Mrs. Giselle Hersh, Division of
Workplace Programs, SAMHSA/CSAP, Room 2-1042, One Choke Cherry Road,
Rockville, Maryland 20857; 240-276-2600 (voice), 240-276-2610 (fax).
SUPPLEMENTARY INFORMATION: The Mandatory Guidelines were initially
developed in accordance with Executive Order 12564 and section 503 of
Public Law 100-71. The ``Mandatory Guidelines for Federal Workplace
Drug Testing Programs'', as amended in the revisions listed above,
requires {or set{time} strict standards that Laboratories and
Instrumented Initial Testing Facilities (IITF) must meet in order to
conduct drug and specimen validity tests on urine specimens for Federal
agencies.
To become certified, an applicant Laboratory/IITF must undergo
three rounds of performance testing plus an on-site inspection. To
maintain that certification, a Laboratory/IITF must participate in a
quarterly performance testing program plus undergo periodic, on-site
inspections.
Laboratories and Instrumented Initial Testing Facilities (IITF) in
the applicant stage of certification are not to be considered as
meeting the minimum requirements described in the HHS Mandatory
Guidelines. A Laboratory/IITF must have its letter of certification
from HHS/SAMHSA (formerly: HHS/NIDA) which attests that it has met
minimum standards.
In accordance with the Mandatory Guidelines dated November 25, 2008
(73 FR 71858), the following Laboratories and Instrumented Initial
Testing Facilities (IITF) meet the minimum standards to conduct drug
and specimen validity tests on urine specimens:
Instrumented Initial Testing Facilities (IITF)
None.
Laboratories
ACL Laboratories >8901 W. Lincoln Ave. West Allis, WI 53227, 414-328-
7840/800-877-7016 (Formerly: Bayshore Clinical Laboratory)
ACM Medical Laboratory, Inc., 160 Elmgrove Park, Rochester, NY 14624,
585-429-2264
Advanced Toxicology Network, 3560 Air Center Cove, Suite 101, Memphis,
TN 38118, 901-794-5770/888-290-1150
Aegis Analytical Laboratories , 345 Hill Ave., Nashville, TN 37210,
615-255-2400 (Formerly: Aegis Sciences Corporation, Aegis Analytical
Laboratories, Inc.)
Alere Toxicology Services, 1111 Newton St., Gretna, LA 70053, 504-361-
8989/800-433-3823 (Formerly: Kroll Laboratory Specialists, Inc.,
Laboratory Specialists, Inc.)
Alere Toxicology Services, 450 Southlake Blvd., Richmond, VA 23236,
804-378-9130 (Formerly: Kroll Laboratory Specialists, Inc., Scientific
Testing Laboratories, Inc.; Kroll Scientific Testing Laboratories,
Inc.)
Baptist Medical Center-Toxicology Laboratory, 11401 I-30, Little Rock,
AR 72209-7056, 501-202-2783 (Formerly: Forensic Toxicology Laboratory
Baptist Medical Center)
Clinical Reference Lab, 8433 Quivira Road, Lenexa, KS 66215-2802, 800-
445-6917
Doctors Laboratory, Inc., 2906 Julia Drive, Valdosta, GA 31602, 229-
671-2281
DrugScan, Inc., P.O. Box 2969, 1119 Mearns Road, Warminster, PA 18974,
215-674-9310
ElSohly Laboratories, Inc., 5 Industrial Park Drive, Oxford, MS 38655,
662-236-2609
[[Page 46310]]
Gamma-Dynacare Medical Laboratories,* A Division of the Gamma-Dynacare
Laboratory Partnership, 245 Pall Mall Street, London, ONT, Canada N6A
1P4, 519-679-1630
Laboratory Corporation of America Holdings, 7207 N. Gessner Road,
Houston, TX 77040, 713-856-8288/800-800-2387
Laboratory Corporation of America Holdings, 69 First Ave., Raritan, NJ
08869, 908-526-2400/800-437-4986 (Formerly: Roche Biomedical
Laboratories, Inc.)
Laboratory Corporation of America Holdings, 1904 Alexander Drive,
Research Triangle Park, NC 27709, 919-572-6900/800-833-3984 (Formerly:
LabCorp Occupational Testing Services, Inc., CompuChem Laboratories,
Inc.; CompuChem Laboratories, Inc., A Subsidiary of Roche Biomedical
Laboratory; Roche CompuChem Laboratories, Inc., A Member of the Roche
Group)
Laboratory Corporation of America Holdings, 1120 Main Street,
Southaven, MS 38671, 866-827-8042/800-233-6339 (Formerly: LabCorp
Occupational Testing Services, Inc.; MedExpress/National Laboratory
Center)
LabOne, Inc. d/b/a Quest Diagnostics, 10101 Renner Blvd., Lenexa, KS
66219, 913-888-3927/800-873-8845 (Formerly: Quest Diagnostics
Incorporated; LabOne, Inc.; Center for Laboratory Services, a Division
of LabOne, Inc.)
Maxxam Analytics,* 6740 Campobello Road, Mississauga, ON, Canada L5N
2L8, 905-817-5700, (Formerly: Maxxam Analytics Inc. NOVAMANN (Ontario),
Inc.)
MedTox Laboratories, Inc., 402 W. County Road D, St. Paul, MN 55112,
651-636-7466/800-832-3244
MetroLab-Legacy Laboratory Services, 1225 NE 2nd Ave., Portland, OR
97232, 503-413-5295/800-950-5295
Minneapolis Veterans Affairs Medical Center, Forensic Toxicology
Laboratory, 1 Veterans Drive, Minneapolis, MN 55417, 612-725-2088
National Toxicology Laboratories, Inc., 1100 California Ave.,
Bakersfield, CA 93304, 661-322-4250/800-350-3515
One Source Toxicology Laboratory, Inc., 1213 Genoa-Red Bluff, Pasadena,
TX 77504, 888-747-3774 (Formerly: University of Texas Medical Branch,
Clinical Chemistry Division; UTMB Pathology-Toxicology Laboratory)
Pacific Toxicology Laboratories, 9348 DeSoto Ave., Chatsworth, CA
91311, 800-328-6942 (Formerly: Centinela Hospital Airport Toxicology
Laboratory)
Pathology Associates Medical Laboratories, 110 West Cliff Dr., Spokane,
WA 99204, 509-755-8991/800-541-7891x7
Phamatech, Inc., 10151 Barnes Canyon Road, San Diego, CA 92121, 858-
643-5555
Quest Diagnostics Incorporated, 1777 Montreal Circle, Tucker, GA 30084,
800-729-6432 (Formerly: SmithKline Beecham Clinical Laboratories;
SmithKline Bio-Science Laboratories)
Quest Diagnostics Incorporated, 400 Egypt Road, Norristown, PA 19403,
610-631-4600/877-642-2216 (Formerly: SmithKline Beecham Clinical
Laboratories; SmithKline Bio-Science Laboratories)
Quest Diagnostics Incorporated, 8401 Fallbrook Ave., West Hills, CA
91304, 800-877-2520 (Formerly: SmithKline Beecham Clinical
Laboratories)
S.E.D. Medical Laboratories, 5601 Office Blvd., Albuquerque, NM 87109,
505-727-6300/800-999-5227
South Bend Medical Foundation, Inc., 530 N. Lafayette Blvd., South
Bend, IN 46601, 574-234-4176 x1276
Southwest Laboratories, 4625 E. Cotton Center Boulevard, Suite 177,
Phoenix, AZ 85040, 602-438-8507/800-279-0027
St. Anthony Hospital Toxicology Laboratory, 1000 N. Lee St., Oklahoma
City, OK 73101, 405-272-7052
STERLING Reference Laboratories, 2617 East L Street, Tacoma, Washington
98421, 800-442-0438
Toxicology & Drug Monitoring Laboratory, University of Missouri
Hospital & Clinics, 301 Business Loop 70 West, Suite 208, Columbia, MO
65203, 573-882-1273
Toxicology Testing Service, Inc., 5426 N.W. 79th Ave., Miami, FL 33166,
305-593-2260
U.S. Army Forensic Toxicology Drug Testing Laboratory, 2490 Wilson St.,
Fort George G. Meade, MD 20755-5235, 301-677-7085
*The Standards Council of Canada (SCC) voted to end its
Laboratory Accreditation Program for Substance Abuse (LAPSA)
effective May 12, 1998. Laboratories certified through that program
were accredited to conduct forensic urine drug testing as required
by U.S. Department of Transportation (DOT) regulations. As of that
date, the certification of those accredited Canadian laboratories
will continue under DOT authority. The responsibility for conducting
quarterly performance testing plus periodic on-site inspections of
those LAPSA-accredited laboratories was transferred to the U.S. HHS,
with the HHS' NLCP contractor continuing to have an active role in
the performance testing and laboratory inspection processes. Other
Canadian laboratories wishing to be considered for the NLCP may
apply directly to the NLCP contractor just as U.S. laboratories do.
Upon finding a Canadian laboratory to be qualified, HHS will
recommend that DOT certify the laboratory (Federal Register, July
16, 1996) as meeting the minimum standards of the Mandatory
Guidelines published in the Federal Register on April 30, 2010 (75
FR 22809). After receiving DOT certification, the laboratory will be
included in the monthly list of HHS-certified laboratories and
participate in the NLCP certification maintenance program.
Dated: July 25, 2011.
Janine Denis Cook,
Chemist, Division of Workplace Programs, CSAP/SAMHSA.
[FR Doc. 2011-19478 Filed 8-1-11; 8:45 am]
BILLING CODE 4160-20-P
